Complement Profiles in Patients with Amyotrophic Lateral Sclerosis: A Prospective Observational Cohort Study

References

• Hardiman O, Al-Chalabi A, Brayne C, et al. The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J Neurol Neurosurg Psychiatry. 2017;88(7):557–563. doi:10.1136/jnnp-2016-314495
   PubMed Web of Science ®Google Scholar
• Kjældgaard AL, Pilely K, Olsen KS, et al. Amyotrophic lateral sclerosis: the complement and inflammatory hypothesis. Mol Immunol. 2018;102:14–25. doi:10.1016/j.molimm.2018.06.007
   PubMed Web of Science ®Google Scholar
• Hawksworth OA, Coulthard LG, Woodruff TM. Complement in the fundamental processes of the cell. Mol Immunol. 2017;84:17–25. doi:10.1016/j.molimm.2016.11.010
   PubMed Web of Science ®Google Scholar
• Magdalon J, Mansur F, Teles ESAL, de Goes VA, Reiner O, Sertié AL. Complement system in brain architecture and neurodevelopmental disorders. Front Neurosci. 2020;14:23. doi:10.3389/fnins.2020.00023
   PubMed Web of Science ®Google Scholar
• Wang C, Yue H, Hu Z, et al. Microglia mediate forgetting via complement-dependent synaptic elimination. Science (New York, NY). 2020;367(6478):688–694. doi:10.1126/science.aaz2288
   Google Scholar
• Vignesh P, Rawat A, Sharma M, Singh S. Complement in autoimmune diseases. Clin Chim Acta. 2017;465:123–130. doi:10.1016/j.cca.2016.12.017
   PubMed Web of Science ®Google Scholar
• Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol. 1992;140(3):691–707.
   PubMed Web of Science ®Google Scholar
• Ferraiuolo L, Heath PR, Holden H, Kasher P, Kirby J, Shaw PJ. Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J Neurosci. 2007;27(34):9201–9219. doi:10.1523/JNEUROSCI.1470-07.2007
   PubMed Web of Science ®Google Scholar
• Annunziata P. Complement alterations in the CSF of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1995;58(3):393. doi:10.1136/jnnp.58.3.393-b
   PubMed Web of Science ®Google Scholar
• Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem. 2011;117(3):528–537. doi:10.1111/j.1471-4159.2011.07224.x
   PubMed Web of Science ®Google Scholar
• Tsuboi Y, Yamada T. Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1994;57(7):859–861. doi:10.1136/jnnp.57.7.859
   PubMed Web of Science ®Google Scholar
• Grewal RP, Morgan TE, Finch CE. C1qB and clusterin mRNA increase in association with neurodegeneration in sporadic amyotrophic lateral sclerosis. Neurosci Lett. 1999;271(1):65–67. doi:10.1016/S0304-3940(99)00496-6
   PubMed Web of Science ®Google Scholar
• Lee JD, Kamaruzaman NA, Fung JN, et al. Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2013;10(1):119. doi:10.1186/1742-2094-10-119
   PubMedGoogle Scholar
• Lee JD, Kumar V, Fung JN, Ruitenberg MJ, Noakes PG, Woodruff TM. Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. Br J Pharmacol. 2017;174(8):689–699. doi:10.1111/bph.13730
   PubMed Web of Science ®Google Scholar
• Lobsiger CS, Boillee S, Cleveland DW. Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc Natl Acad Sci U S A. 2007;104(18):7319–7326. doi:10.1073/pnas.0702230104
   PubMed Web of Science ®Google Scholar
• Heurich B, El Idrissi NB, Donev RM, et al. Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. J Neuroimmunol. 2011;235(1–2):104–109. doi:10.1016/j.jneuroim.2011.03.011
   PubMed Web of Science ®Google Scholar
• Humayun S, Gohar M, Volkening K, et al. The complement factor C5a receptor is upregulated in NFL-/- mouse motor neurons. J Neuroimmunol. 2009;210(1–2):52–62. doi:10.1016/j.jneuroim.2009.01.028
   PubMed Web of Science ®Google Scholar
• Woodruff TM, Costantini KJ, Crane JW, et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008;181(12):8727–8734. doi:10.4049/jimmunol.181.12.8727
   PubMed Web of Science ®Google Scholar
• Woodruff TM, Lee JD, Noakes PG. Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proc Natl Acad Sci U S A. 2014;111(1):E3–4. doi:10.1073/pnas.1321248111
   PubMed Web of Science ®Google Scholar
• Mantovani S, Gordon R, Macmaw JK, et al. Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood. J Neuroimmunol. 2014;276(1–2):213–218. doi:10.1016/j.jneuroim.2014.09.005
   PubMed Web of Science ®Google Scholar
• Xu Z, Lee A, Nouwens A, Henderson RD, McCombe PA. Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotroph Lateral Scler Frontotemporal Degener. 2018;1–15.
   Google Scholar
• Chen X, Feng W, Huang R, et al. Evidence for peripheral immune activation in amyotrophic lateral sclerosis. J Neurol Sci. 2014;347(1–2):90–95. doi:10.1016/j.jns.2014.09.025
   PubMed Web of Science ®Google Scholar
• Goldknopf IL, Sheta EA, Bryson J, et al. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson’s disease. Biochem Biophys Res Commun. 2006;342(4):1034–1039. doi:10.1016/j.bbrc.2006.02.051
   PubMed Web of Science ®Google Scholar
• Apostolski S, Nikolic J, Bugarski-Prokopljevic C, Miletic V, Pavlovic S, Filipovic S. Serum and CSF immunological findings in ALS. Acta Neurol Scand. 1991;83(2):96–98. doi:10.1111/j.1600-0404.1991.tb04656.x
   PubMed Web of Science ®Google Scholar
• Bahia El Idrissi N, Bosch S, Ramaglia V, Aronica E, Baas F, Troost D. Complement activation at the motor end-plates in amyotrophic lateral sclerosis. J Neuroinflammation. 2016;13(1):72. doi:10.1186/s12974-016-0538-2
   PubMedGoogle Scholar
• Mohanty L, Henderson RD, McCombe PA, Lee A. Levels of clusterin, CD5L, ficolin-3, and gelsolin in ALS patients and controls. Amyotroph Lateral Scler Frontotemporal Degener. 2020;1–4.
   Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. doi:10.1371/journal.pmed.0040296
   PubMed Web of Science ®Google Scholar
• Kjældgaard AL, Pilely K, Olsen KS, et al. Amyotrophic lateral sclerosis and the innate immune system: protocol for establishing a biobank and statistical analysis plan. BMJ Open. 2020;10(8):e037753. doi:10.1136/bmjopen-2020-037753
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293–299. doi:10.1080/146608200300079536
   PubMed Web of Science ®Google Scholar
• Bayarri-Olmos R, Kirketerp-Moller N, Perez-Alos L, Skjodt K, Skjoedt MO, Garred P. Development of a quantitative assay for the characterization of human collectin-11 (CL-11, CL-K1). Front Immunol. 2018;9:2238. doi:10.3389/fimmu.2018.02238
   PubMed Web of Science ®Google Scholar
• Bastrup-Birk S, Skjoedt MO, Munthe-Fog L, Strom JJ, Ma YJ, Garred P. Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome. PLoS One. 2013;8(9):e73119. doi:10.1371/journal.pone.0073119
   PubMed Web of Science ®Google Scholar
• Hansen S, Selman L, Palaniyar N, et al. Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity. J Immunol. 2010;185(10):6096–6104. doi:10.4049/jimmunol.1002185
   PubMed Web of Science ®Google Scholar
• Skjoedt MO, Hummelshoj T, Palarasah Y, et al. Serum concentration and interaction properties of MBL/ficolin associated protein-1. Immunobiology. 2011;216(5):625–632. doi:10.1016/j.imbio.2010.09.011
   PubMed Web of Science ®Google Scholar
• Pilely K, Skjoedt MO, Nielsen C, et al. A specific assay for quantification of human C4c by use of an anti-C4c monoclonal antibody. J Immunol Methods. 2014;405:87–96. doi:10.1016/j.jim.2014.01.011
   PubMed Web of Science ®Google Scholar
• Garred P, Mollnes TE, Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol. 1988;27(3):329–335. doi:10.1111/j.1365-3083.1988.tb02354.x
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Lea T, Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol. 1985;22(2):197–202. doi:10.1111/j.1365-3083.1985.tb01871.x
   PubMed Web of Science ®Google Scholar
• Munthe-Fog L, Hummelshoj T, Honore C, et al. Variation in FCN1 affects biosynthesis of ficolin-1 and is associated with outcome of systemic inflammation. Genes Immun. 2012;13:515–522.
   PubMed Web of Science ®Google Scholar
• Munthe-Fog L, Hummelshøj T, Hansen BE, et al. The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand J Immunol. 2007;65(4):383–392. doi:10.1111/j.1365-3083.2007.01915.x
   PubMed Web of Science ®Google Scholar
• Munthe-Fog L, Hummelshøj T, Ma YJ, et al. Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. Mol Immunol. 2008;45(9):2660–2666. doi:10.1016/j.molimm.2007.12.012
   PubMed Web of Science ®Google Scholar
• Garred P, Madsen HO, Kurtzhals JA, et al. Diallelic polymorphism may explain variations of the blood concentration of mannan-binding protein in Eskimos, but not in black Africans. Eur J Immunogen. 1992;19(6):403–412. doi:10.1111/j.1744-313X.1992.tb00083.x
   PubMedGoogle Scholar
• Skjoedt MO, Palarasah Y, Munthe-Fog L, et al. MBL-associated serine protease-3 circulates in high serum concentrations predominantly in complex with Ficolin-3 and regulates Ficolin-3 mediated complement activation. Immunobiology. 2010;215:921–931.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nature Med. 2006;12(6):682–687. doi:10.1038/nm1419
   PubMed Web of Science ®Google Scholar
• Krisinger MJ, Goebeler V, Lu Z, et al. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood. 2012;120(8):1717–1725. doi:10.1182/blood-2012-02-412080
   PubMed Web of Science ®Google Scholar
• Bhakdi S, Fassbender W, Hugo F, et al. Relative inefficiency of terminal complement activation. J Immunol. 1988;141:3117–3122.
   PubMed Web of Science ®Google Scholar
• Yaseen S, Demopulos G, Dudler T, et al. Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2. FASEB J. 2017;31(5):2210–2219. doi:10.1096/fj.201601306R
   PubMed Web of Science ®Google Scholar
• Xu Z, Lee A, Nouwens A, Henderson RD, McCombe PA. Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5–6):362–376. doi:10.1080/21678421.2018.1433689
   PubMed Web of Science ®Google Scholar
• Hansen CB, Bayarri-Olmos R, Kristensen MK, Pilely K, Hellemann D, Garred P. Complement related pattern recognition molecules as markers of short-term mortality in intensive care patients. The J Infect. 2020;80:378–387.
   PubMed Web of Science ®Google Scholar
• Gajek G, Świerzko AS, Cedzyński M. Association of polymorphisms of MASP1/3, COLEC10, and COLEC11 genes with 3MC syndrome. Int J Mol Sci. 2020;21(15):21. doi:10.3390/ijms21155483
   Web of Science ®Google Scholar
• Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177–183. doi:10.1038/nature16549
   PubMed Web of Science ®Google Scholar
• Gaya da Costa M, Poppelaars F, van Kooten C, et al. Age and sex-associated changes of complement activity and complement levels in a healthy Caucasian population. Front Immunol. 2018;9.
   PubMed Web of Science ®Google Scholar
• Balendra R, Al Khleifat A, Fang T, Al-Chalabi A. A standard operating procedure for King’s ALS clinical staging. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3–4):159–164. doi:10.1080/21678421.2018.1556696
   PubMed Web of Science ®Google Scholar